Human MutT Homolog 1 (MTH1) Inhibitor Reduces the Biological Activity of Ovarian Carcinoma Cells

被引:0
|
作者
Zhong, Liyan [1 ]
Yi, Yi [2 ]
Liu, Qian [1 ]
Peng, Yan [1 ]
机构
[1] Xuzhou Med Univ, Wujin Hosp, Wujin Clin Coll, Dept Gynecol,Jiangsu Univ, Changzhou 213017, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Wujin Hosp, Wujin Clin Coll, Dept Oncol,Jiangsu Univ, Changzhou 213017, Jiangsu, Peoples R China
关键词
MTH1 Small-Molecule Inhibitor; Ovarian Carcinoma; TH588; Bax; Bcl-2; Biological Activity; CANCER; APOPTOSIS;
D O I
10.1166/jbt.2022.2993
中图分类号
Q813 [细胞工程];
学科分类号
摘要
This study intends to discuss the mechanism of MTH1 inhibitor (TH588) in the biological activity of ovarian carcinoma cells. A2780 and SKOV-3 cells were treated with different concentrations of TH588 and assigned into AT group (control), BT group (8 mu mol/L TH588), CT group (16 mu mol/L), DT group (32 Amol/L), ET group (64 Amol/L) and FT group (128 mu mol/L) followed by measuring level of Bcl-2 and Bax by Western blot and PCR, and cell biological activities by MTT, FCM and Transwell chamber assay. The cell proliferative rate was not affected in AT group, but was lower in other groups in a reverse dose-dependent manner. There was significant difference on apoptotic rate and cell invasion among groups with increased apoptosis and reduce invasion after TH588 treatment. FT group showed lowest expression of Bcl-2 and Bax compared to other groups. In conclusion, the biological activity of A2780/SKOV3 cells could be reduced by MTH1 inhibitor which was probably through regulation of Bax and Bcl-2 expression.
引用
收藏
页码:907 / 913
页数:7
相关论文
共 50 条
  • [1] MutT Homolog 1 (MTH1): The Silencing of a Target
    Papeo, Gianluca
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (06) : 2343 - 2345
  • [2] Molecular genetics and structural biology of human MutT homolog, MTH1
    Nakabeppu, Y
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2001, 477 (1-2) : 59 - 70
  • [3] Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectives
    Yin, Yizhen
    Chen, Fener
    ACTA PHARMACEUTICA SINICA B, 2020, 10 (12) : 2259 - 2271
  • [4] Targeting human MutT homolog 1(MTH1) for cancer eradication:current progress and perspectives
    Yizhen Yin
    Fener Chen
    ActaPharmaceuticaSinicaB, 2020, 10 (12) : 2259 - 2271
  • [5] Towards a better understanding of human MutT Homolog 1 (MTH1) as a therapeutic target in cancer
    Rai, Priyamvada
    FREE RADICAL BIOLOGY AND MEDICINE, 2018, 128 : S73 - S73
  • [6] Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA-24 with Tumor-Selective Toxicity
    Kang, Nannan
    Ma, Jun
    Hu, Yuling
    Di, Rongrong
    Wang, Lei
    Zhang, Xuanling
    Lai, Yisheng
    Liu, Yu
    PHARMACEUTICALS, 2024, 17 (03)
  • [7] Pharmacological inhibition of MutT homolog 1 (MTH1) in allergic airway inflammation as a novel treatment strategy
    Adler, Anna
    Bergwik, Jesper
    Padra, Medea
    Papareddy, Praveen
    Schmidt, Tobias
    Dahlgren, Madelene
    Kahn, Robin
    Berglund, Ulrika Warpman
    Egesten, Arne
    RESPIRATORY RESEARCH, 2025, 26 (01)
  • [8] MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways
    A Patel
    D G A Burton
    K Halvorsen
    W Balkan
    T Reiner
    C Perez-Stable
    A Cohen
    A Munoz
    M G Giribaldi
    S Singh
    D J Robbins
    D M Nguyen
    P Rai
    Oncogene, 2015, 34 : 2586 - 2596
  • [9] MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways
    Patel, A.
    Burton, D. G. A.
    Halvorsen, K.
    Balkan, W.
    Reiner, T.
    Perez-Stable, C.
    Cohen, A.
    Munoz, A.
    Giribaldi, M. G.
    Singh, S.
    Robbins, D. J.
    Nguyen, D. M.
    Rai, P.
    ONCOGENE, 2015, 34 (20) : 2586 - 2596
  • [10] INHIBITION OF MUTT HOMOLOG 1 (MTH1) IN GLIOBLASTOMA MULTIFORME RESULTS IN IMPAIRED CELL MIGRATION AND TUMOR GROWTH
    Timmer, M.
    Kannampuzha, S.
    Rohn, G.
    Goldbrunner, R.
    NEURO-ONCOLOGY, 2016, 18 : 57 - 57